WO2016036273A1 - Agent médicamenteux pour la prévention et le traitement d'affections des voies respiratoires - Google Patents

Agent médicamenteux pour la prévention et le traitement d'affections des voies respiratoires Download PDF

Info

Publication number
WO2016036273A1
WO2016036273A1 PCT/RU2015/000192 RU2015000192W WO2016036273A1 WO 2016036273 A1 WO2016036273 A1 WO 2016036273A1 RU 2015000192 W RU2015000192 W RU 2015000192W WO 2016036273 A1 WO2016036273 A1 WO 2016036273A1
Authority
WO
WIPO (PCT)
Prior art keywords
alloferon
gly
treatment
drug according
drug
Prior art date
Application number
PCT/RU2015/000192
Other languages
English (en)
Russian (ru)
Inventor
Игорь БЕККЕР
Су Ин КИМ
Борис Алексеевич НИКОНОВ
Андрей Анатольевич ДЫШКОВЕЦ
Герман Петрович БЕККЕР
Original Assignee
Общество с ограниченной ответственностью "Аллоферон"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество с ограниченной ответственностью "Аллоферон" filed Critical Общество с ограниченной ответственностью "Аллоферон"
Publication of WO2016036273A1 publication Critical patent/WO2016036273A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids

Definitions

  • the invention relates to medicine - means and methods of treatment and prevention of diseases of the upper and lower respiratory tract of various etiologies.
  • the invention relates to medicine, to the field of bioorganic chemistry (pharmaceutical industry), namely, to pharmaceuticals based on peptides of the Alloferon group and their biologically active complexes with transition metals, as well as their pharmaceutical compositions for use in medicine as anti-allergic and anti-inflammatory drugs that also have antibacterial, antiviral,
  • anti-inflammatory and anti-destructive actions as well as for the treatment and prevention of acute and chronic inflammatory diseases of the upper and lower respiratory tract of infectious, allergic and mixed etiology: rhinitis, sinusitis, rhinopharyngitis, pharyngitis, tonsillitis, tracheitis, tracheobronchitis, bronchitis, obstructive bronchitis, obstructive bronchitis pneumonia.
  • antibiotics cause a number of side effects, such as upset intestines, allergies, weakening of the immune system and its natural resistance to infections, and also cause toxic effects on internal organs such as the liver, kidneys, bone marrow, etc.
  • one of the objectives of this invention is to develop a new effective drug for the treatment and prevention of diseases of the upper and lower respiratory tract which, among other things, potentiates the effect of antibacterial drugs.
  • Bronchial asthma is a chronic inflammatory disease of the airways characterized by various symptoms such as airway obstruction, bronchial hyperreactivity and inflammation. Asthma occurs as a response to various irritants: antigens, pollutants, cold air and direct physical effects.
  • the treatment of asthma consists in suppressing bronchial obstruction or bronchospasm, inflammatory processes, as well as in eliminating the effects of allergens.
  • the total number of patients with bronchial asthma worldwide is from 4 to 10% of the population (Ovcharenko S. I. Bronchial asthma: diagnosis and treatment. - breast cancer, 2002. — T. 10. — N2 17).
  • glucocorticosteroids antagonists of leukotriene receptors, xanthines, monoclonal anti-IgE antibodies and combinations of these drugs.
  • the sensitivity to the drug used decreases, which forces you to prescribe drugs in increased doses, increase the frequency of use of the drug, or select a new, more effective drug.
  • glucocorticosteroids that suppress the production of anti-inflammatory cytokines, reduce the number of inflammatory cells, inhibit their activation and migration.
  • the use of glucocorticosteroids occurs mainly by inhalation (topical steroids) or orally. Their long-term inhalation use often leads to the appearance of such side effects as hoarseness of the voice, candidiasis of the nasal cavity, nasopharynx, oral cavity and trachea, dermatological diseases, Quincke's edema, immunosuppression.
  • glucocorticosteroids leads to bradycardia, increased blood pressure, dizziness, headaches, cramps, nausea and vomiting, immunosuppression, development of (steroid) stomach ulcers, Itsenko-Cushing's syndrome, diabetes mellitus, osteoporosis, impaired function of the adrenal glands, level, to the appearance of skin diseases such as contact eczema, etc.
  • ⁇ 2-adrenergic agonists are often used to treat asthma, which relax the smooth muscles of the bronchi, which leads to a decrease in symptoms and easier breathing.
  • 2-adrenergic agonists have side effects such as heart rhythm disturbances, headaches, abdominal pain, nausea and vomiting.
  • Monotherapy with 2-adrenergic agonists is prescribed less and less, while combinations of glucocorticosteroids with ⁇ -2-adrenergic agonists are the most popular drugs for the treatment of asthma and clinic-like chronic obstructive pulmonary diseases. This is subsequently accompanied by an increase in the frequency of side effects characteristic of both groups of these drugs.
  • Antagonists Antagonists
  • leukotriene receptors expand the bronchi and reduce the inflammatory process, this effect is based on the blockade of signals of leukotriene receptors. Therefore, these drugs can be used as an adjunct to the main therapy together with glucocorticosteroids and ⁇ 2-3 ⁇ ⁇ ⁇ 3 ⁇ , in order to relieve the residual symptoms of asthma.
  • the main side effects of leukotriene receptor antagonists are abdominal pain, nausea and vomiting, headaches, cough, and drug hepatitis.
  • Xanthines are also used to relieve spasms of the bronchi. But they also have a number of undesirable side effects: dizziness, headaches, decreased sleep, overexcitation and irritability, tremor of extremities, arrhythmias, lowering blood pressure, pain in the heart and stomach,
  • allergic diseases such as bronchial asthma, especially with a predominance of the allergic component, mixed asthma, year-round allergic rhinitis, seasonal allergic rhinitis, chronic obstructive airways diseases (chronic obstructive bronchitis,
  • compositions based on peptides of the Alloferon group and their biologically active complexes with transition metals can be administered topically, injection, intranasally, inflation, oral and rectally in the form of standard dosage forms containing
  • ARVI is the group of the most common infectious diseases in developed countries. An adult, on average, suffers from SARS at least 2-3 times a year, at preschool age children suffer from SARS from 6 to 12 times a year (G.Z. Piskunov, S.Z.
  • influenza vaccines are complicated, therefore it is important to always have funds for the prevention and treatment of diseases that are caused
  • nucleoside analogues which, as a rule, are effective, but for a number of compounds of nucleoside analogues with antiviral activity, the development of resistance of viruses to them is characteristic.
  • drugs are used in the world.
  • the first generation of such drugs include adamantane-type drugs that are blockers of the ion channels formed by the M2 protein of the influenza virus.
  • Commonly used drugs include adamantane-type drugs that are blockers of the ion channels formed by the M2 protein of the influenza virus.
  • adamantane derivatives are therapeutically and prophylactically effective in the treatment of diseases caused by influenza A virus, but at the same time lead to a number of side effects.
  • Second-generation drugs include neuraminidase inhibitors (zanamivir), which are used in the form of an aerosol, and
  • Oseltamivir which is used in capsule and suspension form for children and adults, is effective against both influenza A virus and influenza B virus, but their use is also often associated with the occurrence of side effects.
  • H5N1 subtype Nl neuraminidase
  • His274Tyr and N294S Nl neuraminidase
  • rhinitis divides them into acute and chronic forms. In chronic form, the inflammatory process can be caused
  • infectious rhinitis in diseases such as diphtheria, scleroma, tuberculosis, syphilis, etc. are relatively rare.
  • Acute Infectious Rhinitis in diseases such as diphtheria, scleroma, tuberculosis, syphilis, etc.
  • rhinitis caused by viruses, and chronic rhinitis is caused by bacteria and sometimes fungi.
  • the atrophic form of rhinitis is noteworthy, a significant pathogenesis of which is played by a specific pathogen - Klebsiella. Damaging factors such as surgical trauma, chemical and physical factors can cause infectious rhinitis. In these cases, bacteria are a secondary etiological factor that affects the mucous membrane that is damaged and devoid of its protective mechanisms.
  • rhinovirus infection is characterized by isolated foci of the affected epithelium, while the main part of the mucous membrane remains intact.
  • atrophic and hypertrophic forms are rarely found separately.
  • chronic catarrh of the nasal cavity can turn into a subatrophic / atrophic or hypertrophic form.
  • hyperplasia of the submucous layer of the mucous membrane often occurs with atrophic changes in the epithelium or, in another case, with an increase in the number of glands and hyperproduction of mucus.
  • Hypertrophic changes mainly concern the lower nasal concha which, increasing in size, gradually occupy all the lower parts of the nasal cavity. Hypertrophy can be either local or filling in mostly the back of the shells, which in this case acquire a polypous form.
  • allergic rhinitis is a disease of the nasal mucosa, which is based on allergic inflammation, which is caused by causative allergens with clinical symptoms such as rhinorrhea, nasal congestion, itching nasopharyngeal cavities and frequent sneezing. Manifestations of conjunctivitis, headache and impaired sense of smell are also possible.
  • antibacterial agents include corticosteroids and / or vasoconstrictors. In addition to these drugs, in addition to direct bactericidal action, they also have anti-inflammatory and desensitizing effects. Moreover, the constituent corticosteroids have a number of side effects described above.
  • Interferon is almost the only antiviral drug that is used for injection into the nasal cavity.
  • Local vasoconstrictor drugs are used in the form of drops and aerosols and act on the regulation of the tone of the blood vessels of the nasal cavity. At the same time, they activate adrenergic receptors, which in turn leads to a reduction in the cavernous tissue of the nasal concha, which leads to the expansion of the nasal passages and improved nasal breathing. Therefore, the availability of drugs for the treatment of acute infectious rhinitis and chronic infectious rhinitis is currently quite diverse. Moreover, one of the disadvantages of these drugs is that they do not affect the mechanisms that underlie the chronicity of the disease, which is
  • atrophic processes in the nasal mucosa and nasopharynx adjust local immunity.
  • WO 2006/107957 describes a device for the treatment of diseases of the paranasal sinuses
  • the cavity element, the nasal part and the element of the mouth contain biologically compatible material.
  • the biocompatible material contains a biodegradable polymer.
  • the biodegradable polymer can be selected from the group consisting of polyamino acids.
  • One or more active substances may be selected from the group consisting of peptides, nucleic acids, or a combination thereof.
  • the aim of the present invention is to expand the use of drugs based on peptides of the Alloferon group and their biologically active complexes with transition metals by spreading their antiviral action to other viruses - the causative agents of acute respiratory viral infections.
  • the technical result of the invention is a pharmaceutical composition having the properties of providing anti-allergic, anti-inflammatory, antibacterial, antiviral, immunomodulating (interferonogenic), cytoprotective and anti-destructive effects on the human body during use for the prevention and treatment of acute and chronic inflammatory diseases of the upper and lower respiratory tract of an infectious, allergic and mixed etiology.
  • the oligopeptides of the Alloferon group or biologically active peptide complexes of Alloferon with transition metals where the active component of the aloferon group is represented by the formula: X HiS-Gly- X 2 -HiS-Gly-Val-Xs, where Xi is absent or contains at least one amino acid, where X 2 contains at least 1 amino acid or is a peptide bond and where X 3 contains at least one amino acid or is absent; and biologically active peptide complexes of Alloferons with transition metals
  • Xi is absent or contains at least 1 amino acid
  • R1 and R2 are peptide chains, containing amino acid residues
  • N ++ is one of the transition metal ions (such as Cu, Zn, etc.).
  • a medicament may contain the above peptides in the form of pharmaceutically acceptable salts, esters or amides.
  • a drug based on the above peptides may include pharmaceutically acceptable carriers, stabilizers or diluents.
  • the active component is Alloferon-1, having the structural formula:
  • the drug is preferably performed:
  • SOD superoxide dismutase
  • mucosal permeability enhancers preferably superoxide dismutase (SOD) and / or pharmaceutically acceptable mucosal permeability enhancers are included.
  • pathology is pneumonia, acute respiratory viral infections and influenza.
  • an effective amount of the drug in any combination depending on the weight of the patient and the individual tolerance of the components of the composition, characterized in that they use a drug based on peptides of the Alloferon group and their biologically active complexes with transition metals.
  • a patient in need of such treatment is preferably administered repeatedly with an effective amount of the drug.
  • the introduction of the drug is carried out by any of the following methods: by inhalation, orally, intranasally, by injection and locally.
  • the goal and the claimed result is achieved by the fact that the ability to induce interferons ⁇ and ⁇ found in these drugs allows them to be used to treat acute respiratory viral infections, regardless of the virus that caused the disease.
  • the influenza virus is the most common cause of SARS.
  • preparations based on peptides of the Alloferon group and their biologically active complexes with transition metals will have a double therapeutic effect: as chemotherapeutic drugs and as interferon inducers.
  • drugs based on peptides of the Alloferon group and their biologically active complexes with transition metals increase the effectiveness of antibiotic therapy in the treatment of diseases of the upper and lower respiratory tract.
  • Said antibacterial therapy may also include the administration of at least one antibacterial agent.
  • a significant group of pathologies of acute and chronic inflammatory diseases of the upper and lower respiratory tract of infectious, allergic and mixed etiology is a wide group of diseases.
  • the implementation of the invention is a wide group of diseases.
  • the proposed tool is also based on the discovery by the authors of the above-mentioned anti-influenza agents of the ability to suppress the reproduction of influenza viruses.
  • Peptides of the Alloferon group and their biologically active complexes with transition metals and their pharmaceutical compositions are able to induce the synthesis of endogenous interferon in patients. Stimulating the level of endogenous interferon is more effective in the treatment of viral diseases than exogenous (donor) interferon, since the use of an interferon inducer does not lead to excessive formation of interferon, which, in turn, provides
  • interferon inducers are used in the first hours of the disease that are effective against all viral pathogens of acute respiratory viral infections, regardless of their type. Since the most important part in the pathogenesis of acute respiratory viral infections is changes in the place of the mucous membrane of the nose and nasopharynx, it is quite justified to use the drug locally, intranasally or orally.
  • a promising direction in the treatment of influenza patients is the use of drugs that stimulate the production of endogenous interferons, i.e. interferon inducers.
  • interferon inducers does not require repeated administration and they do not have antigenic activity. Also, they have practically no side effects inherent in interferon drugs.
  • using interferon inducers one can achieve stimulation of the production of own interferons in the body in concentrations that have a high
  • Alloferon-1, Alloferon-2, Cu ++ - Alloferon-1 and Zn ++ - Alloferon-1 were administered for three days once a day to experimental groups of guinea pigs by inhalation (using a nebulizer ⁇ in doses of 40 ⁇ g / kg
  • the control group received physical. solution.
  • the intensity of the bronchospastic reaction of animals was recorded 1 hour after the last administration of the test compounds, when ovalbumin was inhaled using a nebulizer and the duration and intensity were evaluated
  • inhalation at a dose of 40 ⁇ g / kg showed a high antianaphylactic activity, while inhalation administration of Zn ++ - Alloferon-1 at a dose of 40 ⁇ g / kg completely inhibited the development of the acute phase of the bronchoconstrictor reaction, which, causing suffocation, caused death in animals.
  • Immunization of guinea pigs was carried out according to a certain scheme for 2 months by intraperitoneal administration of ovalbumin at a dose of 10 mg / kg with a 5-day interval. After that, the animals were inhaled with a nebulizer using a solution of ovalbumin in increasing concentration, starting from 0.1% to 1% with an interval of 3 days between inhalations.
  • the inhalation form using a nebulizer technique for 6 days on the 6th day of administration provoked a reaction with the ovalbumin antigen.
  • a model of allergic pneumonia in guinea pigs was used.
  • Test compounds (0.1% rp) were inhaled daily with a nebulizer within 5 days. Antigen challenge provoked on the 5th day.
  • the experiments were performed on 180 white mice weighing 11-15 g.
  • the mice were infected intranasally under ether anesthesia with the influenza virus A / California / 07/09 (H1N1) (10 LD50).
  • the test substances were administered peros at a dose of 40 and 20 mg / kg / day. Therapy was carried out according to the scheme: 24 hours and 3 hours before infection, then 1 time per day (at 10 a.m.) for 7 days.
  • the therapeutic activity of Alloferon-1, Alloferon-2, C ++ - Alloferon-1 and Zn ++ - Alloferon-1 in an animal influenza pneumonia model was evaluated by two indicators such as protection against fatal viral infection and an increase in the average life expectancy of treated animals in comparison with a control group.
  • the therapy was carried out in the form of inhalation Alloferon-1 - OD% 3 times a day for 7 days; cefotaxime - 2.0 g intramuscularly 3 times a day for 7 days.
  • procalcitonin after a course of treatment completely normalized.
  • a patient with bacterial pneumonia confirmed by the presence of bacterial infection markers was successfully treated.
  • LPS lipopolysaccharide
  • the studied substances were administered up to 9 days after the first administration of LPS, i.e. total Alloferon-1, Alloferon-2, Cu ++ - Alloferon-1 and Zn ++ - Alloferon-1 were administered 12 days (3 days before induction of ARDS and 9 times during and after induction).
  • dexamethasone was carried out according to the following scheme: 48, 24 and 1 hour before the induction of ARDS in a dose of 5 mg / kg, 3 days after the first injection of LPS in the same dose and drug withdrawal with a gradual decrease over 3 days. Thus, dexamethasone was administered 9 times.
  • Patients of group I (30 patients) received Alloferon-1 aerosol (lmg / 10 mlNaCI) per day for 5 days and standard therapy, including antibacterial (penicillin 1 g. X 4 times / m 7 days), pathogenetic and symptomatic agents .
  • Sick I! groups (30 patients) received Alloferon-2 aerosol (lmg / 10 mlNaCi) per day for 5 days and standard therapy, including antibacterial (penicillin 1 g. x 4 times IM for 7 days), pathogenetic and symptomatic agents.
  • Group III patients (30 patients) received Ci ++ Aerosol - Alloferon-1 (lmg / 10 mlNaCI) per day for 5 days and standard therapy, including
  • Group IV patients (30 patients) received Zn ++ - Alloferon-1 aerosol (lmg / 10 mlNaCI) per day for 5 days and standard therapy, including
  • Group V patients (30 patients) received only standard therapy.
  • Criteria of clinical effectiveness terms of normalization of temperature; the timing of the disappearance of symptoms of intoxication; inflammatory changes in the oropharynx;
  • Alloferon-1, Alloferon-2, C ++ - Alloferon-1 and Zn ++ - Alloferon-1 has an excellent safety profile, side effects did not occur in any of the cases.
  • a clinical blood test was taken from the patients and the blood levels of leukocytes, lymphocytes, hemoglobin, neutrophils, monocytes were determined, and ESR was measured.
  • Alloferon-1, Alloferon-2, Cu ++ - Alloferon-1 and Zn ++ - Alloferon-1 were 1 mg of substance / day per patient, according to the clinical trial regimen. In this case, the patient was injected with an inhaler 2-4 aerosol injections into the nose or mouth every 2-3 hours.
  • the temperature in patients taking Alloferon-1 occurred on average after 2.52 days, in those taking Alloferon-2 - after 3.10 days, in those taking C ++ - Alloferon-1 - after 2.81 days and Zn + + -Alloferon-1 occurred on average 2.31 days, and in control patients not taking Alloferon-1, Alloferon-2, Cu ++ - Alloferon-1 and Zn ++ - Alloferon-1 after 4.2 days ( p ⁇ 0.05).
  • the duration of the common cold was, respectively, with Alloferon-1 - 2.51 days, with Alloferon-2 - 3.25 days, with C ++ - Alloferon-1 - 2.75 days and with Zn ++ - Alloferon-1 - 2.21 and with placebo - 4.52 days (p ⁇ 0.05).
  • the duration of sore throat with Alloferon-1 is -2.25 days, with Alloferon-2 - 2.85 days, with C ++ - Alloferon-1 - 2.50 days and with Zn ++ - Alloferon-1 - 2.13 days, and with placebo - 3.19 days (p ⁇ 0.05).
  • Hyperemia of the oropharynx mucosa with Alloferon-1 stopped for 4.55 days, with Alloferon-2 for 5.22 days, C ++ - Alloferon-1 for 4.83 days and Zn ++ - Alloferon for 4.37 days, and control patients after 5.92 days (p ⁇ 0.05). Also, tonsil reduction and pharyngeal wall granularity reduction occurred during treatment with Alloferon-1, Alloferon-2, Cu ++ - Alloferon-1 OR Zn ++ - Alloferon-1 faster than in patients treated without these drugs.
  • ARVI therapy with inhalation Alloferon-1, Alloferon-2, C ++ - Alloferon-1 and Zn ++ - Alloferon-1 reduces the recovery time and the risks of bacterial complications, as well as improves the quality of life of the patient during the disease. Compared with standard therapy, this is manifested in a decrease in the duration of the clinical manifestations of acute respiratory viral infections by 17-54%.
  • the influenza virus ceased to be detected in nasal swabs on average 3-4 days after the start of treatment with Alloferon-1, Alloferon-2, Cu ++ - Alloferon-1 and Zn ++ - Alloferon-1.
  • ovalbumin-specific IgE antibodies using a special device for monitoring the concentration of IgE in ng / ml (OVA-specific IgE ELISA Kit).
  • mice of the BALB / C line were used, middle age 4-6 weeks, 12 animals per group. Mice were sensitized by intraperitoneal injection of ovalbumin in aluminum hydroxide at doses of 0.3 ml per mouse on days 1 and 9. On days 18, 22 and 26, mice were inhaled with ovalbumin (7%) for 30 minutes in a special room.
  • dexamethasone was used, which was administered orally for ten days (from 18 to 27 days) for half an hour of inhalation with ovalbumin, while the studied compounds were also inhaled for ten days (from 18 to 27 days) half an hour before inhalation of ovalbumin.
  • an asthma attack was triggered by inhalation of methacholine.
  • Plethysmography was used to determine the effect of the drugs, while exhalation and inspiration pressure and temporary respiration parameters were measured on special equipment. From which the Z index was derived. The results are shown in table 8.
  • Alloferon-1 aerosol was used as a prophylactic and immunostimulating drug. The drug was taken three times a day in the form of an aerosol. In the study group there were no revealed diseases of influenza and acute respiratory viral infections.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention se rapporte au domaine de la médecine et concerne notamment des agents et des procédés de prévention et de traitement des affections des voies respiratoires supérieures et inférieures de diverses étiologies. Cet agent médicamenteux comprend des peptides du groupe des alloférines ou de complexes peptidiques biologiquement actifs dans une quantité efficace. Le composant actif du groupe des alloférines correspond à la formule X1-His-Gly-X2-His-Gly-Val-Х3, où X1 est absent ou comprend au moins un acide aminé, X2 comprend au moins un acide aminé ou consiste en une liaison peptidique, X3 comprend au moins un acide aminé ou est absent.
PCT/RU2015/000192 2014-09-05 2015-03-27 Agent médicamenteux pour la prévention et le traitement d'affections des voies respiratoires WO2016036273A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2014136096A RU2014136096A (ru) 2014-09-05 2014-09-05 Лекарственное средство для лечения и профилактики заболеваний верхних и нижних дыхательных путей различной этиологии, его применение и метод лечения на его основе
RU2014136096 2014-09-05

Publications (1)

Publication Number Publication Date
WO2016036273A1 true WO2016036273A1 (fr) 2016-03-10

Family

ID=55440177

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2015/000192 WO2016036273A1 (fr) 2014-09-05 2015-03-27 Agent médicamenteux pour la prévention et le traitement d'affections des voies respiratoires

Country Status (2)

Country Link
RU (1) RU2014136096A (fr)
WO (1) WO2016036273A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018124933A1 (fr) * 2016-12-29 2018-07-05 Герман Петрович БЕККЕР Composition pour préparer un agent antitumoral et procédé de préparation d'agent antitumoral l'utilisant
RU2742565C1 (ru) * 2019-12-29 2021-02-08 Герман Петрович Беккер Фармацевтическая композиция, содержащая биологически активные комплексы аллоферона с цинком, и способ ее получения

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2737852C2 (ru) * 2017-12-28 2020-12-03 Беккер Герман Петрович Способ получения лекарственного средства на основе олигопептида аллоферона-1, имеющего противовирусную и иммуномодулирующую направленность, и лекарственное средство увеличенного срока хранения, полученное с его помощью
WO2022108471A1 (fr) * 2020-11-20 2022-05-27 Герман Петрович БЕККЕР Agent pour le traitement et la prévention d'infections virales respiratoires aiguës

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2172322C1 (ru) * 1999-12-27 2001-08-20 Энтофарм Ко., Лтд. Аллофероны-иммуномодулирующие пептиды
RU2482866C2 (ru) * 2010-10-07 2013-05-27 Общество с ограниченной ответственностью "Аллоферон" Способ лечения папилломавирусных инфекций, реализуемый через индукцию интерлейкина-18

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2172322C1 (ru) * 1999-12-27 2001-08-20 Энтофарм Ко., Лтд. Аллофероны-иммуномодулирующие пептиды
RU2482866C2 (ru) * 2010-10-07 2013-05-27 Общество с ограниченной ответственностью "Аллоферон" Способ лечения папилломавирусных инфекций, реализуемый через индукцию интерлейкина-18

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FALLER P. ET AL.: "Bioinorganic chemistry of copper and zinc ions coordinated to amyloidbeta peptide''.", DALTON TRANS, no. 7, 2009, pages 1080 - 1094 *
KOWALIK-JANKOWSKA T. ET AL.: "Mononuclear copper (II) complexes of alloferons 1 and 2: a combined potentiometric and spectroscopic studies''.", J INORG BIOCHEM, vol. 103, no. 1, 2009, pages 135 - 145, XP025710459, DOI: doi:10.1016/j.jinorgbio.2008.09.013 *
SIDWELL RW ET AL.: "Inhibitory effects of recombinant manganese superoxide dismutase on influenza virus infections in mice''.", ANTIMICROB AGENTS CHEMOTHER., vol. 40, no. 11, 1996, pages 2626 - 31 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018124933A1 (fr) * 2016-12-29 2018-07-05 Герман Петрович БЕККЕР Composition pour préparer un agent antitumoral et procédé de préparation d'agent antitumoral l'utilisant
RU2667128C2 (ru) * 2016-12-29 2018-09-14 Герман Петрович Беккер Композиция для приготовления противоопухолевого средства и способ приготовления противоопухолевого средства на ее основе
CN110139660A (zh) * 2016-12-29 2019-08-16 杰尔曼·彼得罗维奇·贝克尔 用于制备抗肿瘤剂的组合物以及用于制备基于所述组合物的抗肿瘤剂的方法
US11166908B2 (en) 2016-12-29 2021-11-09 German Petrovich Bekker Composition for preparing an anti-tumour agent and a method for preparing an anti-tumour agent on the basis of same
RU2742565C1 (ru) * 2019-12-29 2021-02-08 Герман Петрович Беккер Фармацевтическая композиция, содержащая биологически активные комплексы аллоферона с цинком, и способ ее получения
WO2021137722A1 (fr) * 2019-12-29 2021-07-08 Герман Петрович БЕККЕР Composition pharmaceutique contenant des complexes bio-actifs d'alloférone avec du zinc

Also Published As

Publication number Publication date
RU2014136096A (ru) 2016-03-27

Similar Documents

Publication Publication Date Title
US7238661B2 (en) Oral lactoferrin in the treatment of respiratory disorders
JP6952379B2 (ja) 急性ウイルス性呼吸器疾患を治療するための経鼻医薬組成物
WO2016036273A1 (fr) Agent médicamenteux pour la prévention et le traitement d'affections des voies respiratoires
WO2011159821A1 (fr) Utilisation de la lévocétirizine et du montélukast dans le traitement de la grippe, du rhume et d'une inflammation
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
ES2285238T3 (es) Combinacion de etabonato de loteprednol y dfho para el tratamiento de enfermedades de las vias respiratorias, enfermedades alergicas, asma y copd.
CN116710109A (zh) 治疗纤维化的方法
WO2021212183A1 (fr) Produits de fabrication et procédés de traitement, d'amélioration ou de prévention d'infections microbiennes
AU2009254262B2 (en) Compositions for the treatment of disorders of the upper respiratory tract and influenza syndromes
CN107663158B (zh) 奥司他韦羧酸盐酸盐及其雾化剂的制备方法
MXPA04002066A (es) Farmacos contra influenza.
CN112074291A (zh) 预防和治疗呼吸道疾病的组合物
ES2507570T3 (es) Terapia de combinación de Zn/trimetoprim
WO2021218154A1 (fr) Médicament, aliment et application contre l'infection à coronavirus
WO2015135372A1 (fr) Utilisation de l'isoforskoline dans le cadre de la prévention et du traitement de la bronchopneumopathie obstructive chronique
CN101375851A (zh) 生物碱类化合物在制备治疗咳嗽药物中的用途
US20040191327A1 (en) Method of treating and/or preventing asthma using natural compound luteolin
WO2024120452A1 (fr) Compositions et méthodes de prophylaxie et de traitement de la covid-19
CN112805027B (zh) 一种抗新冠病毒感染的药物与应用
RU2190422C1 (ru) Аэрозоль для ингаляций фармацевтической композиции глутовент и способ лечения с его использованием
UA55355A (uk) Спосіб лікування та профілактики загострень бронхіальної астми, поєднаної з вірусною та грибковою інфекцією
IT202000011983A1 (it) Composizione per la prevenzione e il trattamento delle affezioni delle vie respiratorie e come stimolante del sistema immunitario
CN118871100A (zh) 抗病毒治疗剂及其用途
WO2021084058A1 (fr) Composition pour la prévention et le traitement de maladies du système respiratoire
CN115443126A (zh) 用于预防或治疗SARS-CoV-2感染的相容性溶质

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15837533

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15837533

Country of ref document: EP

Kind code of ref document: A1